Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 4;228(Suppl 1):S55-S69.
doi: 10.1093/infdis/jiad174.

COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future

Victoria G Hall  1   2 , Benjamin W Teh  1   2
Affiliations
Review

COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future

Victoria G Hall et al. J Infect Dis. .

Abstract

Patients with cancer demonstrate an increased vulnerability for infection and severe disease by SARS-CoV-2, the causative agent of COVID-19. Risk factors for severe COVID-19 include comorbidities, uncontrolled disease, and current line of treatment. Although COVID-19 vaccines have afforded some level of protection against infection and severe disease among patients with solid tumors and hematologic malignancies, decreased immunogenicity and real-world effectiveness have been observed among this population compared with healthy individuals. Characterizing and understanding the immune response to increasing doses or differing schedules of COVID-19 vaccines among patients with cancer is important to inform clinical and public health practices. In this article, we review SARS-CoV-2 susceptibility and immune responses to COVID-19 vaccination in patients with solid tumors, hematologic malignancies, and those receiving hematopoietic stem cell transplant or chimeric-antigen receptor T-cell therapy.

Keywords: chimeric-antigen receptor T-cell therapy; hematologic malignancies; hematopoietic stem cell transplant; mRNA COVID-19 vaccines; solid tumors.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. V. G. H. is supported by a National Health and Medical Research Council postgraduate PhD scholarship (Number 2014210). B. W. T. has participated on advisory boards for Moderna, CSL-Behring, and Takeda, and received grants from Seqirus and MSD, honoraria from Pfizer, Alexion, and Janssen, and is supported by the Australian Government Medical Research Future Fund Fellowship. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Summary of the range of pooled antibody response rates after 2 doses of COVID-19 vaccines across hematologic malignancies [38–40]. Seroresponse rates will vary depending on other factors including disease treatment status, type of therapy, and timing of vaccination. Red represents the lowest seroresponse rate observed and blue represents the highest seroresponse rate observed. ANHL, aggressive non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; HL, Hodgkin lymphoma; INHL, indolent non-Hodgkin lymphoma; MM, multiple myeloma; MPN, myeloproliferative neoplasms.
Figure 2.
Figure 2.
Summary of the range of pooled antibody response rates after 2 doses of COVID-19 vaccines in patients who received hematopoietic stem cell transplant (HSCT) or chimeric antigen receptor T-cell therapy (CAR-T) [16, 52–54]. Seroresponse rates will vary depending on other factors including disease treatment status, type of therapy, and timing of vaccination. Red represents the lowest seroresponse rate observed and blue represents the highest seroresponse rate observed. alloHSCT, allogeneic HSCT; autoHSCT, autologous HSCT.
See this image and copyright information in PMC

References

    1. Yang L, Chai P, Yu J, Fan X. Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants. Cancer Biol Med 2021; 18:298–307. - PMC - PubMed
    1. Fattore GL, Olivos NSA, Olalla JEC, Gomez L, Marucco AF, Mena MPR. Mortality in patients with cancer and SARS-CoV-2 infection: results from the Argentinean Network of Hospital-Based Cancer Registries. Cancer Epidemiol 2022; 79:102200. - PMC - PubMed
    1. Ohm JE, Carbone DP. Immune dysfunction in cancer patients. Oncology (Williston Park) 2002; 16:11–8. - PubMed
    1. Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 2020; 395:1919–26. - PMC - PubMed
    1. Kong X, Qi Y, Huang J, et al. Epidemiological and clinical characteristics of cancer patients with COVID-19: a systematic review and meta-analysis of global data. Cancer Lett 2021; 508:30–46. - PMC - PubMed

Publication types

Substances